Hydrochloric Acid → (S)-1-(3-chloro-6-(6-(5-ethylpyridin-3-yl)-1H-pyrazolo[4,3-c]pyridin-1-yl)pyridin-2-yl)piperidin-3-amine
Reaktionsgleichung
[Cl:1][C:2]1[C:3]([N:25]2[CH2:30][CH2:29][CH2:28][C@H:27]([NH:31]C(=O)OC(C)(C)C)[CH2:26]2)=[N:4][C:5]([N:8]2[C:16]3[CH:15]=[C:14]([C:17]4[CH:18]=[N:19][CH:20]=[C:21]([CH2:23][CH3:24])[CH:22]=4)[N:13]=[CH:12][C:11]=3[CH:10]=[N:9]2)=[CH:6][CH:7]=1.Cl>CO.O1CCOCC1>[Cl:1][C:2]1[C:3]([N:25]2[CH2:30][CH2:29][CH2:28][C@H:27]([NH2:31])[CH2:26]2)=[N:4][C:5]([N:8]2[C:16]3[CH:15]=[C:14]([C:17]4[CH:18]=[N:19][CH:20]=[C:21]([CH2:23][CH3:24])[CH:22]=4)[N:13]=[CH:12][C:11]=3[CH:10]=[N:9]2)=[CH:6][CH:7]=1Komponenten
Edukt 2
Produkt 1
Reagenzien, Katalysatoren, Lösungsmittel 2
Versuchsvorschrift
To a solution of tert-butyl N-[(3S)-1-[3-chloro-6-[6-(5-ethyl-3-pyridyl)pyrazolo[4,3-c]pyridin-1-yl]-2-pyridyl]-3-piperidyl]carbamate (0.0446 mmol; 23.8 mg) in Methanol (10 mL) was added hydrochloric acid, 4.0 M in 1,4-Dioxane (5 mL). The resulting mixture was stirred at room temperature overnight. The mixture was concentrated and the residue was purified by reverse phase HPLC to afford 117 (7.0 mg, 33%). 1H NMR (400 MHz, DMSO) δ 9.36-9.31 (s, 1H), 9.18-9.11 (m, 2H), 8.74-8.65 (s, 1H), 8.58-8.52 (d, J=1.9 Hz, 1H), 8.34-8.30 (s, 1H), 8.02-7.97 (d, J=8.4 Hz, 1H), 7.60-7.55 (d, J=8.4 Hz, 1H), 3.95-3.81 (dd, J=27.5, 10.2 Hz, 2H), 3.06-2.97 (t, J=10.2 Hz, 1H), 2.93-2.84 (t, J=9.5 Hz, 1H), 2.81-2.72 (m, 3H), 1.98-1.90 (d, J=12.6 Hz, 1H), 1.89-1.80 (d, J=13.3 Hz, 1H), 1.79-1.68 (d, J=12.9 Hz, 1H), 1.68-1.48 (s, 2H), 1.31-1.26 (t, J=7.6 Hz, 3H), 1.26-1.20 (m, 1H); MS (ESI) m/z: 434.2 [M+H]+
Aufarbeitung
- concentrationThe mixture was concentrated
- customthe residue was purified by reverse phase HPLC
Quellen und Nachweise
- ORD-Eintrag
- ord-0aeeb7424afc4353b1f43c875563f77c
- Quelldatensatz
- uspto-grants-2016_09
- Patentnummer
- US09434725B2
Notizen zur Reaktion
Wird geladen…